
Daridorexant HCl(cas:1792993-84-0)was originally developed by Swiss companies Actelion Ltd. and Idorsia Ltd..It was first launched in the US on January 7, 2022 for the treatment of insomnia. It selectively targets orexin neurons and inhibits downstream neuronal pathways that promote wakefulness.Compared with lemborexant, it shares the same mechanism of action yet has a shorter half-life with minimal hangover effect.
×